Circle Pharma announces $92.5 million Series E financing led by The Column Group to advance their Cyclin D1 program into clinical development.
Amount Raised
$92.5 Million
Round Type
Series E
South San FranciscoHealthcareHealth CareInvestors
Description
Circle Pharma, a clinical-stage biopharmaceutical company, has successfully raised $92.5 million in an oversubscribed Series E financing. The funding was led by The Column Group with participation from existing and new investors including Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly. The proceeds will be used to advance their first-in-class Cyclin D1 program. This financing marks a significant step forward in their efforts to develop targeted macrocycle therapeutics for cancer.
Quick answer
Circle Pharma raised $92.5 Million in a Series E round, dated September 16, 2026. Investors: Euclidean Capital, Eli Lilly And Company, RA Capital Management, Nextech Invest and The Column Group. Circle Pharma is based in South San Francisco, California, United States.
- How much did Circle Pharma raise?
- Circle Pharma raised $92.5 Million in a Series E round on September 16, 2026.
- Who invested in Circle Pharma?
- Euclidean Capital, Eli Lilly And Company, RA Capital Management, Nextech Invest and The Column Group are named as investors in this round.
- What does Circle Pharma do?
- Circle Pharma is a biotechnology company creating bioavailable macrocyclic peptide therapeutics that target protein-protein interactions.
- Where is Circle Pharma based and how big is it?
- Circle Pharma is based in South San Francisco, California, United States. Fundz records about 41 employees.
- Who are the decision-makers at Circle Pharma?
- Fundz holds 2 contacts at Circle Pharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Health Care around the same time
Companies in the same sectors as Circle Pharma that raised within 45 days of this round, from Fundz verified event records.
- Actuate Therapeutics raised $10M (Post-IPO Equity) on October 28, 2026.
- Endovia Health Sciences, Inc. raised $135M (Post-IPO Equity) on October 27, 2026.
- Os Therapies raised $7.2M on October 15, 2026.
- Recursion Pharmaceuticals raised $200M (Post-IPO Equity) on October 15, 2026.
- Ospitek raised an undisclosed amount on October 13, 2026.
- Sunshine Biopharma raised $6M (Post-IPO Equity) on October 9, 2026.
Who to call at Circle Pharma, and when
A new round usually means Circle Pharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Circle Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Circle Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Circle Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Circle Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Circle Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.